Tagged with IMI

Hungary Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon’s first company-developed biosimilar in Japan.   Our advancement in biotechnology has been a key development for Gedeon Richter this year…

Hungary István Hodász, CEO of Egis Pharmaceuticals PLC, introduces the longstanding history of the company and its positioning as a leading manufacturer of value-added generics with a strong presence in the CEE market. Hodász goes on to highlight the company’s recent milestones, including manufacturing investments, portfolio acquisitions, new therapeutic area strategies,…

Czech Republic Sandoz’s Jiří Hanzlík, country head for the Czech Republic, evaluates the Czech affiliate’s role in contributing to the success of Sandoz globally as well as its position in the country. He delves into the growth of their biosimilars business — its portfolio share increased from eight to 15 percent in…

Hungary Jānis Meikšāns, newly appointed general manager of Teva Hungary, speaks about his first few months in the country. Meikšāns goes on to elaborate on Hungary’s key positioning as a strategic affiliate for Teva with strong R&D and manufacturing operations. Additionally, he highlights Teva’s longstanding commitment to the country not only…

Hungary Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in biologics R&D.   Biosimilars in Europe Over the past decade, over 80 biologic molecules have been launched worldwide. By 2020…

USA The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and increase patient access to lifesaving medications.     In a nutshell: competition brings prices down across the board Biologic drugs…

Switzerland Indian generics powerhouse Dr. Reddy’s has prioritized biosimilars as a key component of the global organization’s ongoing transition into a specialty pharma company.   As one of the first companies in the developing world to branch out into this segment – launching four biosimilar products between 2001 and 2011 –…

Generics Christoph Stoller, general manager for Austria and Germany at Teva was recently elected president of Medicines for Europe, the continent-wide association for the generics and biosimilars industries. Stoller plans to focus his efforts on improving access to generics and biosimilars in Europe, as well as tackling the damaging issue of…

China Dr. Zhengyu Yuan, president & CEO of MicuRx, shares the story of how MicuRx was founded in 2007 to develop new and innovative antimicrobial drugs; their flagship product, contezolid, which recently concluded Phase III trials in China; and their future plans for an IPO.   We combined US experience and…

Korea The nation of South Korea has overtaken many of its regional counterparts to boast a highly impressive biosimilars pipeline. Here, key stakeholders in Korean biologics and biosimilars explain how.   Once we chose to specialise in biosimilars, there was no room to survive if we failed with the few projects…

Korea ISU Abxis is a biotech company founded in 2001 with a focus on orphan drugs and rare disease. Part of the ISU chaebol, ISU Abxis has leveraged its parent company’s long-standing expertise in chemicals.   We have penetrated the Korean market already, and have received approval in 12 overseas emerging…

Pricing Generic drugs foster competition in the pharmaceutical market. Chester “Chip” Davis, Jr.  of the Association for Accessible Medicines (AAM) reveals the data behind generic competition and elaborates on opportunities for further savings.    The American public is clamoring for systemic changes to address skyrocketing drug prices. Specialty drugs—a growing category…